Comparative study on the effects of kynurenic acid and glucosamine-kynurenic acid
Kynurenic acid (KYNA) is the only known endogenous N-methyl-D-aspartate (NMDA) receptor inhibitor and might therefore come into consideration as a therapeutic agent in certain neurobiological disorders. However, its use as a neuroprotective compound is practically excluded because KYNA does not read...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2004
|
| Sorozat: | PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
77 No. 1 |
| doi: | 10.1016/j.pbb.2003.10.001 |
| mtmt: | 105674 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/10111 |
| LEADER | 02551nab a2200337 i 4500 | ||
|---|---|---|---|
| 001 | publ10111 | ||
| 005 | 20190508164331.0 | ||
| 008 | 161219s2004 hu o 0|| zxx d | ||
| 022 | |a 0091-3057 | ||
| 024 | 7 | |a 10.1016/j.pbb.2003.10.001 |2 doi | |
| 024 | 7 | |a 105674 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Füvesi Judit | |
| 245 | 1 | 0 | |a Comparative study on the effects of kynurenic acid and glucosamine-kynurenic acid |h [elektronikus dokumentum] / |c Füvesi Judit |
| 260 | |c 2004 | ||
| 300 | |a 95-102 | ||
| 490 | 0 | |a PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR |v 77 No. 1 | |
| 520 | 3 | |a Kynurenic acid (KYNA) is the only known endogenous N-methyl-D-aspartate (NMDA) receptor inhibitor and might therefore come into consideration as a therapeutic agent in certain neurobiological disorders. However, its use as a neuroprotective compound is practically excluded because KYNA does not readily cross the blood-brain barrier (BBB). We recently synthetized a new compound, glucosamine-kynurenic acid (KYNA-NH-GLUC), which is presumed to cross the BBB more easily. In this study, the effects of KYNA and KYNA-NH-GLUC on behavior and cortical activity were investigated in adult rats. The results show that (1) on intracerebroventricular application, the behavioral changes induced by KYNA and by KYNA-NH-GLUC are quite similar; (2) on intravenous administration, KYNA (25 mg/kg) has no effect on the somatosensory-evoked cortical potentials, whereas KYNA-NH-GLUC (25 mg/kg) causes transient but appreciable reductions in the amplitudes of the evoked responses within 5 min after application; and (3) the results of in vitro studies demonstrated that both KYNA and KYNA-NH-GLUC reduced the amplitudes of the field excitatory postsynaptic potentials (fEPSPs). These observations suggest that the two compounds have similar effects, but that KYNA-NH-GLUC passes the BBB much more readily than does KYNA. These results imply that the conjugated NH-GLUC is of importance in the passage across the BBB. (C) 2003 Elsevier Inc. All rights reserved. | |
| 700 | 0 | 1 | |a Somlai Csaba |e aut |
| 700 | 0 | 1 | |a Németh Hajnalka |e aut |
| 700 | 0 | 1 | |a Varga Hedvig |e aut |
| 700 | 0 | 1 | |a Kis Zsolt |e aut |
| 700 | 0 | 1 | |a Farkas Tamás |e aut |
| 700 | 0 | 1 | |a Károly Norbert |e aut |
| 700 | 0 | 1 | |a Dobszay Márton |e aut |
| 700 | 0 | 1 | |a Penke Zsuzsa |e aut |
| 700 | 0 | 1 | |a Penke Botond |e aut |
| 700 | 0 | 1 | |a Vécsei László |e aut |
| 700 | 0 | 1 | |a Toldi József |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/10111/1/Fuvesi_J._Comperative_study_u.pdf |z Dokumentum-elérés |